4.7 Review

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen

Journal

JOURNAL OF PERSONALIZED MEDICINE
Volume 7, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/jpm7040020

Keywords

pharmacogenomics; warfarin; tamoxifen; cytochrome P450

Funding

  1. Wolfe Medical Research Chair in Pharmacogenomics
  2. Canadian Institutes of Health Research, Drug Safety and Effectiveness Network (DSEN-PREVENT) [FRN-117588]
  3. Ontario Research Fund-Research Excellence Round 8

Ask authors/readers for more resources

The use of pharmacogenomics to personalize drug therapy has been a long-sought goal for warfarin and tamoxifen. However, conflicting evidence has created reason for hesitation in recommending pharmacogenomics-guided care for both drugs. This review will provide a summary of the evidence to date on the association between cytochrome P450 enzymes and the clinical end points of warfarin and tamoxifen therapy. Further, highlighting the clinical experiences that we have gained over the past ten years of running a personalized medicine program, we will offer our perspectives on the utility and the limitations of pharmacogenomics-guided care for warfarin and tamoxifen therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available